Gerresheimer AG, a prominent German provider of systems and solutions for the pharmaceutical, biotech, and cosmetic sectors, announced on Monday that the U.S. Food and Drug Administration (FDA) has granted tentative approval to SQ Innovation Inc. for Lasix ONYU. This product, designed for the home management of fluid overload in patients with congestive heart failure, has taken a significant step forward in the regulatory process.
Lasix ONYU, from the Swiss biopharmaceutical company SQ Innovation, is an innovative combination product. It features a novel high-concentration formulation of the diuretic furosemide, paired with Gerresheimer's advanced on-body drug delivery device specifically designed for market readiness. This device, developed and manufactured by Gerresheimer, underscores their influence in the sector.
The FDA's tentative approval signifies that Lasix ONYU complies with the U.S. quality, safety, and efficacy standards necessary for market authorization. However, full approval is currently on hold due to an existing market exclusivity for a competing product in the U.S., which will last until October 2025.
Upon the expiration of the exclusivity period, SQ Innovation intends to pursue full FDA approval. Following this, the initial market availability of Lasix ONYU products is projected for the end of 2025.
This innovative infusor comprises two components: a reusable electromechanical part and a single-use sterile disposable part, which interacts with the drug solution and the patient’s body. Gerresheimer developed the cartridge-based infusor, leveraging its proprietary platform for subcutaneous drug delivery.
Dietmar Siemssen, CEO of Gerresheimer, commented, "The FDA's decision highlights the readiness of our on-body drug delivery technology. It is a testament to our leadership in providing innovative solutions, ranging from product design to regulatory approval and large-scale production. Our on-body devices cater to both small molecule drug formulations and larger biologicals, enabling us to partner with clients who are navigating the growing trend of home treatment. Additionally, these devices offer connectivity to remote therapeutic monitoring platforms."
On the XETRA market, Gerresheimer's shares were valued at 76.60 euros, reflecting an increase of 0.86 percent.
The material has been provided by InstaForex Company - www.instaforex.com
Lasix ONYU, from the Swiss biopharmaceutical company SQ Innovation, is an innovative combination product. It features a novel high-concentration formulation of the diuretic furosemide, paired with Gerresheimer's advanced on-body drug delivery device specifically designed for market readiness. This device, developed and manufactured by Gerresheimer, underscores their influence in the sector.
The FDA's tentative approval signifies that Lasix ONYU complies with the U.S. quality, safety, and efficacy standards necessary for market authorization. However, full approval is currently on hold due to an existing market exclusivity for a competing product in the U.S., which will last until October 2025.
Upon the expiration of the exclusivity period, SQ Innovation intends to pursue full FDA approval. Following this, the initial market availability of Lasix ONYU products is projected for the end of 2025.
This innovative infusor comprises two components: a reusable electromechanical part and a single-use sterile disposable part, which interacts with the drug solution and the patient’s body. Gerresheimer developed the cartridge-based infusor, leveraging its proprietary platform for subcutaneous drug delivery.
Dietmar Siemssen, CEO of Gerresheimer, commented, "The FDA's decision highlights the readiness of our on-body drug delivery technology. It is a testament to our leadership in providing innovative solutions, ranging from product design to regulatory approval and large-scale production. Our on-body devices cater to both small molecule drug formulations and larger biologicals, enabling us to partner with clients who are navigating the growing trend of home treatment. Additionally, these devices offer connectivity to remote therapeutic monitoring platforms."
On the XETRA market, Gerresheimer's shares were valued at 76.60 euros, reflecting an increase of 0.86 percent.
The material has been provided by InstaForex Company - www.instaforex.com